Recruiting

Liquid Biopsy

Sponsor:

Yale University

Code:

NCT07689864

Conditions

Molecular Residual Disease

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.

Conditions

Molecular Residual Disease

Cancer

Study ID

NCT07689864

Start date

Aug 25, 2026

Status verified date

Aug, 2026

Completion date

Aug, 2031

Anticipated

Primary completion date

Aug, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and/or significant family history of malignancy).
  • Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY.
  • If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence.

Exclusion Criteria:

  • Inability to provide informed consent.
  • Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).

Study Design

Enrollment

2500 participants

Anticipated

Interventions and Outcome Measures

Arms

UNIFY

Patients enrolled in UNIFY only, with biological samples and limited clinical data collected as stipulated by this protocol

UNIFY plus

UNIFY plus a co-enrolled primary research study: Patients concurrently enrolled in a separate IRB-approved under UNIFY, limited clinical data will be collected for this cohort under the primary research study that requires blood sampling and optional or mandatory tumor tissue collection for research purposes.

Primary outcome measure

  • Collection and annotation of biospecimens [ Time Frame: Through study completion, up to 5 years ]

Central Contacts and Locations

Central contacts

Mitchell Elliott, MD

475-375-7981Mitchell.elliott@yale.edu

Locations

Smilow Cancer Hospital

Recruiting

New Haven, Connecticut, United States, 06519

More Information

Sponsor

Yale University

Last update posted

Aug 25, 2026

Last verified

Aug, 2026

Keywords

  • Liquid Biopsy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Yale University on 2026-08-25.